Abstract
A randomized evaluation of a left ventricular assist device (LVAD) for treating congestive heart failure in the REMATCH (randomized evaluation of mechanical assistance for the treatment of congestive heart failure) trial revealed that the device was effective against end-stage heart failure. This finding will accelerate the use of LVAD implants in Japan, where the number of patients who undergo heart transplants is lower than that in the USA or European countries, and the wait for heart transplantation is far longer in Japan than in the USA. Therefore, in addition to the avoidance of complications, the maintenance of well-controlled physical function for those waiting for a heart transplant is important. Neuromuscular electrical stimulation is a good method for reducing skeletal muscle protein degradation and for improving physical function. We aimed to provide new rehabilitation methods using neuromuscular electrical stimulation in patients with an LVAD.
